Cargando…
DNA Double-Strand Break Repair Inhibitors: YU238259, A12B4C3 and DDRI-18 Overcome the Cisplatin Resistance in Human Ovarian Cancer Cells, but Not under Hypoxia Conditions
Cisplatin (CDDP) is the cornerstone of standard treatment for ovarian cancer. However, the resistance of ovarian cancer cells to CDDP leads to an inevitable recurrence. One of the strategies to overcome resistance to CDDP is the combined treatment of ovarian cancer with CDDP and etoposide (VP-16), a...
Autores principales: | Macieja, Anna, Gulbas, Izabela, Popławski, Tomasz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605129/ https://www.ncbi.nlm.nih.gov/pubmed/37886943 http://dx.doi.org/10.3390/cimb45100500 |
Ejemplares similares
-
DDRI-9: a novel DNA damage response inhibitor that blocks mitotic progression
por: Jun, Dong Wha, et al.
Publicado: (2016) -
Packed Red Blood Cell Supernatants Do Not Promote Growth or Cisplatin Resistance of Myeloid Leukemia K-562 Cells
por: Czubak-Prowizor, Kamila, et al.
Publicado: (2022) -
Responses of human colon and breast adenocarcinoma cell lines (LoVo, MCF7) and non-tumorigenic mammary epithelial cells (MCF-10A) to the acellular fraction of packed red blood cells in the presence and absence of cisplatin
por: Czubak-Prowizor, Kamila, et al.
Publicado: (2022) -
Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair
por: Xiao, Man, et al.
Publicado: (2017) -
Dental methacrylates may exert genotoxic effects via the oxidative induction of DNA double strand breaks and the inhibition of their repair
por: Blasiak, Janusz, et al.
Publicado: (2012)